Home > Press Releases

Press Releases (Page 5)

Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein

NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on the second $10 million convertible note pursuant to a financing agreement entered in September, 2021, with Richard E. Uihlein, the Company’s Chairman and largest individual stockholder. In total, the Company has received $30 million in... ❯❯❯

Extendicare Announces December 2021 Dividend of C$0.04 per Share

MARKHAM, Ontario, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of December 2021, which is payable on January 17, 2022 to shareholders of record at the close of business on December 31, 2021. This dividend is designated as an “eligible dividend”... ❯❯❯

Treatment Signs Ocean Medical Agreement For The AI Driven Doctors Office

VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Treatment.com International Inc. (“Treatment or the (“Company”) (CSE: TRUE • OTC: TREIF • 939.F) is a healthcare technology company with a passion for supporting consumers and health care providers globally with easy, AI-driven solutions. Today Treatment announces the first sale of its Treatment Primary Care Module, powering the next generation of... ❯❯❯

Sienna Announces December Dividend

MARKHAM, Ontario, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of December 2021, representing $0.936 per Common Share on an annualized basis. The dividend will be payable on January 14, 2022 to shareholders of record as at December 31, 2021. The Company's... ❯❯❯

SeaSpine Appoints Seasoned Healthcare Executive to its Board of Directors

CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has appointed Angela Steinway to its Board of Directors, effective December 14, 2021. Ms. Steinway will serve as a member of the company’s Audit Committee. With the appointment of Ms. Steinway, the SeaSpine... ❯❯❯

LifeLabs named one of the top employers in Greater Toronto for 2022

Toronto, Ontario, Dec. 14, 2021 (GLOBE NEWSWIRE) -- LifeLabs has been named one of the top employers in Greater Toronto for 2022 by Mediacorp Canada Inc. LifeLabs was selected as one of Greater Toronto's Top Employers (2022) for several reasons, including our employee recognition campaign that highlighted their extraordinary efforts through the pandemic by profiling customer messages of gratitude and appreciation, our recognition... ❯❯❯

MEDIROM Healthcare Technologies Inc., Announces its latest Key Performance Indicators (KPIs)

NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare Company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, updated for the month of November 2021. Data is provided for all salons for which comparative financial and customer data is available and excludes certain salons where such information is not available. ... ❯❯❯

Allarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North

Press release Hørsholm, Denmark (December 13, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that Nasdaq First North Growth Market Sweden (“Nasdaq First North”) has accepted the Company’s application to delist the shares of Allarity A/S. Allarity A/S submitted the application immediately after publishing the Company’s press release of December 11, 2021, announcing the intention... ❯❯❯

Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting

NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal and Ari Rosenberg, both of the University of Chicago Medical Center, engaged to advise on path forward in oncology Cancer immunotherapy efforts likely to focus on Head and Neck cancers Shareholders approved all proposals, including... ❯❯❯

Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North

Press release   Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders have accepted the Share Swap Offer, announced on November 24 and expired on December 9, pending final reconciliation. Considering the very high acceptance rate, the Board of Directors has as of today resolved to complete the... ❯❯❯